Stoke Therapeutics (NASDAQ:STOK) Given New $40.00 Price Target at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK) had its price objective raised by Needham & Company LLC from $35.00 to $40.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently commented on the stock. Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Monday, January 5th. Wedbush increased their target price on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a report on Monday, December 15th. Finally, Guggenheim initiated coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They issued a “buy” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.83.

Stoke Therapeutics Trading Down 3.2%

Shares of Stoke Therapeutics stock opened at $32.87 on Tuesday. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $40.22. The company has a market cap of $1.88 billion, a P/E ratio of 49.06 and a beta of 1.07. The stock has a 50-day moving average price of $32.69 and a 200 day moving average price of $29.89.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, March 17th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). The business had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $5.32 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, equities analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the sale, the insider directly owned 31,339 shares of the company’s stock, valued at approximately $1,253,560. The trade was a 12.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the completion of the transaction, the director directly owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. The trade was a 10.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,203 shares of company stock valued at $1,517,541 in the last quarter. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. RTW Investments LP grew its holdings in shares of Stoke Therapeutics by 8.3% during the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after buying an additional 423,331 shares in the last quarter. Morgan Stanley boosted its position in Stoke Therapeutics by 0.3% during the 4th quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after acquiring an additional 9,108 shares during the last quarter. Vanguard Group Inc. boosted its position in Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after acquiring an additional 217,616 shares during the last quarter. State Street Corp grew its stake in shares of Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Stoke Therapeutics by 7.9% during the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after acquiring an additional 168,771 shares in the last quarter.

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Analysts raised targets and ratings — Needham raised its price target from $35 to $40 and maintains a “buy” rating; Wedbush raised its target from $36 to $38 and keeps an “outperform” rating, signaling continued analyst confidence and potential upside. Analyst Price Target Raises
• Neutral Sentiment: Company granted inducement stock options (58,650 options to six new hires effective March 16, 2026) — this helps recruit talent but adds potential future dilution. Inducement Grants Release
• Negative Sentiment: Quarterly results missed expectations — EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.32M expected. The revenue shortfall and wider EPS miss are the clearest drivers of downward pressure on the share price. Quarterly Earnings Report
• Negative Sentiment: Insider sale — Director Arthur A. Levin sold 605 shares at an average $36.80, reducing his holdings by ~12.5%. The sale is relatively small in dollar terms but may be interpreted negatively by some investors. SEC Form 4

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.